Head-activator and the neuroectodermal differentiation of P19 mouse embryonal carcinoma cells

P19 embryonal carcinoma cells differentiate into neuroectodermal derivates upon aggregation and treatment with retinoic acid (RA). Such RA-induced P19 cells, concomitant with neuronal differentiation, produce the neuropeptide head activator (HA) and release HA into the culture medium. The amount of...

Full description

Saved in:
Bibliographic Details
Published in:Neuroscience letters 1996-03, Vol.207 (1), p.49-52
Main Authors: Niemann, Stephan, Chica Schaller, H.
Format: Article
Language:English
Subjects:
Animals
Biological and medical sciences
Calcium - metabolism
Cell Differentiation
Cell differentiation, maturation, development, hematopoiesis
Cell Division
Cell physiology
Fluorescent Antibody Technique
Fundamental and applied biological sciences. Psychology
Mice
Molecular and cellular biology
Neuroectodermal differentiation
Neuropeptide head activator
Neuropeptides - biosynthesis
P19 cells
Pyrrolidonecarboxylic Acid - analogs & derivatives
Tretinoin - pharmacology
Tumor Cells, Cultured
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:P19 embryonal carcinoma cells differentiate into neuroectodermal derivates upon aggregation and treatment with retinoic acid (RA). Such RA-induced P19 cells, concomitant with neuronal differentiation, produce the neuropeptide head activator (HA) and release HA into the culture medium. The amount of HA produced by such differentiating P19 cells is more than 100-fold higher than that of uninduced P19 cells. RA-induced P19 cells respond to HA treatment with a two-fold increase in total number of neuronally differentiating P19 progeny. As early response to HA, an increase in intracellular calcium concentration is observed.
ISSN:0304-3940
1872-7972
DOI:10.1016/0304-3940(96)12485-X